American Cancer Society: CMS Investigative Study to Examine Benefit of Multi-Cancer Early Detection Tests for Medicare Beneficiaries
November 21, 2023
November 21, 2023
WASHINGTON, Nov. 21 -- The American Cancer Society issued the following news release:
Grail, LLC announced this morning that the Centers for Medicare and Medicaid Services (CMS) and Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) study for the company's Galleri multi-cancer early detection (MCED) test to evaluate the technology's capacity to reduce late-stage cancer diagnoses for the large group of cancers without a traditional screeni . . .
Grail, LLC announced this morning that the Centers for Medicare and Medicaid Services (CMS) and Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) study for the company's Galleri multi-cancer early detection (MCED) test to evaluate the technology's capacity to reduce late-stage cancer diagnoses for the large group of cancers without a traditional screeni . . .